Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rapid Micro Biosystems (RPID) EBITDA Margin (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed EBITDA Margin for 6 consecutive years, with 108.23% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 1624.0% to 108.23% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 141.1% through Dec 2025, up 3686.0% year-over-year, with the annual reading at 141.1% for FY2025, 3686.0% up from the prior year.
  • EBITDA Margin hit 108.23% in Q4 2025 for Rapid Micro Biosystems, up from 145.09% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 108.23% in Q4 2025 to a low of 394.6% in Q4 2022.
  • Historically, EBITDA Margin has averaged 232.4% across 5 years, with a median of 198.08% in 2024.
  • Biggest five-year swings in EBITDA Margin: plummeted -18742bps in 2022 and later skyrocketed 20227bps in 2023.
  • Year by year, EBITDA Margin stood at 279.49% in 2021, then plummeted by -41bps to 394.6% in 2022, then skyrocketed by 51bps to 192.33% in 2023, then skyrocketed by 35bps to 124.47% in 2024, then rose by 13bps to 108.23% in 2025.
  • Business Quant data shows EBITDA Margin for RPID at 108.23% in Q4 2025, 145.09% in Q3 2025, and 167.28% in Q2 2025.